Incidence and Outcomes of Bone Metastases. Evaluation of BTAs Therapy, Pain Relief and Quality of Life: Experience from a Single Cancer Center

Introduction and objective: Morbidity and mortality from malignant diseases are usually the result of metastasis. In this study our aim was to demonstrate the importanceof BTAs therapy on QoLin bone metastatic patients with “long term survival”. Material and Methods: This is aretrospective study of patients with metastatic bone disease, conducted between January 2011 and June 2016. A total of 590patients (51.0% males, 49.0% females) had metastatic bone disease, with the highest incidence between the age range of 60–69 years. Results: The commonest primary cancer was breast (34 %), followed by prostate (27 %), lung (18,%), colon (5%), others (16%) . The majority (90 %) were symptomatic, with pain as the most common symptom and 69% of the patients had manifestations of SRE. Conclusion: In our study, breast and prostate cancers were the commonest primary cancers in metastatic bone disease. Mostpatients had more than one site of involvement and pain at the time of presentation. Well-timed use of Target Therapy (BTAs) allowed us to determine animprovement of clinical benefits and quality of life in these patients, as well as a reduction in the number of hospitalization days related tocomplications (SREs).